ES2717757T3 - Compuestos - Google Patents
Compuestos Download PDFInfo
- Publication number
- ES2717757T3 ES2717757T3 ES15743645T ES15743645T ES2717757T3 ES 2717757 T3 ES2717757 T3 ES 2717757T3 ES 15743645 T ES15743645 T ES 15743645T ES 15743645 T ES15743645 T ES 15743645T ES 2717757 T3 ES2717757 T3 ES 2717757T3
- Authority
- ES
- Spain
- Prior art keywords
- pyrrolo
- ethoxy
- methanone
- amino
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O Chemical compound C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O 0.000 description 4
- ZGJVSCMCFKGKEW-UHFFFAOYSA-N CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 ZGJVSCMCFKGKEW-UHFFFAOYSA-N 0.000 description 1
- FJNNNKKFKHEAET-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 FJNNNKKFKHEAET-UHFFFAOYSA-N 0.000 description 1
- MYLZMKPYMYDDHN-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 MYLZMKPYMYDDHN-UHFFFAOYSA-N 0.000 description 1
- DNLMWWLLGMTQII-UHFFFAOYSA-N CCOc1nc(Cl)nc2c1cn[nH]2 Chemical compound CCOc1nc(Cl)nc2c1cn[nH]2 DNLMWWLLGMTQII-UHFFFAOYSA-N 0.000 description 1
- KPSBLSBABRIUJP-UHFFFAOYSA-N CCOc1ncnc2c1cc[nH]2 Chemical compound CCOc1ncnc2c1cc[nH]2 KPSBLSBABRIUJP-UHFFFAOYSA-N 0.000 description 1
- IXUCYGQTKDSONM-UHFFFAOYSA-N COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O Chemical compound COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O IXUCYGQTKDSONM-UHFFFAOYSA-N 0.000 description 1
- KMWMHGDGKNFOMV-UHFFFAOYSA-N [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O Chemical compound [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O KMWMHGDGKNFOMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000140 | 2014-01-29 | ||
| PCT/CN2015/000054 WO2015113451A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717757T3 true ES2717757T3 (es) | 2019-06-25 |
Family
ID=53756223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15743645T Active ES2717757T3 (es) | 2014-01-29 | 2015-01-28 | Compuestos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815841B2 (esLanguage) |
| EP (1) | EP3099694B1 (esLanguage) |
| JP (1) | JP6474826B2 (esLanguage) |
| CN (1) | CN105980388B (esLanguage) |
| AU (2) | AU2015210554A1 (esLanguage) |
| CA (1) | CA2937430A1 (esLanguage) |
| ES (1) | ES2717757T3 (esLanguage) |
| RU (1) | RU2016134751A (esLanguage) |
| WO (1) | WO2015113451A1 (esLanguage) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029774B1 (ru) | 2014-01-29 | 2018-05-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| JP2020505397A (ja) | 2017-01-25 | 2020-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｒｒｋ２キナーゼ活性を阻害するための化合物 |
| WO2018137619A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US11208412B2 (en) | 2017-02-22 | 2021-12-28 | Daegu-Gyeongbuk Medical Innovation Foundation | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease |
| AU2018239798B2 (en) * | 2017-03-23 | 2020-08-27 | Daegu Gyeongbuk Institute Of Science And Technology | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
| WO2020149723A1 (ko) * | 2019-01-18 | 2020-07-23 | 주식회사 보로노이 | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN113557237B (zh) * | 2019-01-18 | 2025-01-14 | 沃若诺伊公司 | 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途 |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| US12479847B2 (en) | 2019-05-16 | 2025-11-25 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 |
| CN111205216B (zh) * | 2020-03-11 | 2022-03-29 | 连云港恒运药业有限公司 | 一种制备沙格列汀的方法 |
| CA3197034A1 (en) * | 2020-10-29 | 2022-05-05 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| CA3214360A1 (en) | 2021-03-23 | 2022-09-29 | Halia Therapeutics, Inc. | Pyrimidine derivatives useful as lrrk2 kinase inhibitors |
| TW202330549A (zh) | 2021-10-27 | 2023-08-01 | 丹麥商Ｈ 朗德貝克公司 | Lrrk2抑制劑 |
| CN115108991B (zh) * | 2022-06-30 | 2023-05-05 | 南京理工大学 | 一种硝仿基吡唑起爆药及其制备方法 |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| WO2007042298A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| ES2659725T3 (es) * | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
| ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| DK2576541T3 (en) * | 2010-06-04 | 2016-05-30 | Hoffmann La Roche | Aminopyrimidine AS LRRK2 MODULATORS |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| SI2638031T1 (en) | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| TWI606049B (zh) * | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
| EP2758402B9 (en) | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
| CN104093426B (zh) | 2011-11-30 | 2019-06-28 | 健泰科生物技术公司 | 用于lrrk2的正电子发射体层摄影(pet)成像的氟-18和碳-11标记的放射性配体 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| BR112014026952B1 (pt) | 2012-05-03 | 2022-03-15 | Genentech, Inc | Derivados de aminopirimidina pirazol e composição que os compreende |
| AU2013282869B2 (en) * | 2012-06-29 | 2015-12-24 | Pfizer Inc. | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
| EA029774B1 (ru) | 2014-01-29 | 2018-05-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
-
2015
- 2015-01-28 ES ES15743645T patent/ES2717757T3/es active Active
- 2015-01-28 US US15/114,857 patent/US9815841B2/en not_active Expired - Fee Related
- 2015-01-28 EP EP15743645.2A patent/EP3099694B1/en active Active
- 2015-01-28 AU AU2015210554A patent/AU2015210554A1/en not_active Abandoned
- 2015-01-28 JP JP2016549113A patent/JP6474826B2/ja not_active Expired - Fee Related
- 2015-01-28 WO PCT/CN2015/000054 patent/WO2015113451A1/en not_active Ceased
- 2015-01-28 CA CA2937430A patent/CA2937430A1/en not_active Abandoned
- 2015-01-28 CN CN201580006294.1A patent/CN105980388B/zh not_active Expired - Fee Related
- 2015-01-28 RU RU2016134751A patent/RU2016134751A/ru not_active Application Discontinuation
-
2018
- 2018-01-12 AU AU2018200271A patent/AU2018200271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015113451A1 (en) | 2015-08-06 |
| US20170022204A1 (en) | 2017-01-26 |
| CN105980388A (zh) | 2016-09-28 |
| EP3099694A4 (en) | 2017-06-14 |
| AU2018200271A1 (en) | 2018-02-01 |
| AU2015210554A1 (en) | 2016-07-07 |
| CN105980388B (zh) | 2018-01-16 |
| EP3099694B1 (en) | 2019-01-16 |
| EP3099694A1 (en) | 2016-12-07 |
| US9815841B2 (en) | 2017-11-14 |
| CA2937430A1 (en) | 2015-08-06 |
| RU2016134751A (ru) | 2018-03-02 |
| JP6474826B2 (ja) | 2019-02-27 |
| JP2017504635A (ja) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717757T3 (es) | Compuestos | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| JP6745824B2 (ja) | 複素環化合物 | |
| EP2883875B1 (en) | N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing the same as active ingredient for preventing or treating cancer | |
| JP2020526543A (ja) | ロイシンリッチリピートキナーゼ２の阻害剤 | |
| TW200835481A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
| WO2018137607A1 (en) | Compounds | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| JP6698633B2 (ja) | 複素環化合物 | |
| BR112015017759B1 (pt) | Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos | |
| CN101679306B (zh) | 治疗神经变性疾病的杂芳基酰胺取代的嘧啶酮衍生物 | |
| BR112019015273A2 (pt) | compostos | |
| KR20160106623A (ko) | 화합물 | |
| US20140155375A1 (en) | Novel compounds | |
| CN105481862A (zh) | Flt3激酶的新型抑制剂及其用途 | |
| BR112019015278A2 (pt) | compostos | |
| US20190389850A1 (en) | Compounds | |
| HK40019825A (en) | Therapeutic compounds and compositions, and methods of use thereof |